These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 9286820)

  • 21. Longitudinal screening for prostate cancer with prostate-specific antigen.
    Smith DS; Catalona WJ; Herschman JD
    JAMA; 1996 Oct 23-30; 276(16):1309-15. PubMed ID: 8861989
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PSA screening: the bottom line.
    Elhilali MM
    CMAJ; 2000 Mar; 162(6):791-2. PubMed ID: 10750466
    [No Abstract]   [Full Text] [Related]  

  • 23. Indications for PSA testing.
    Barry MJ; Roberts RG
    JAMA; 1997 Mar; 277(12):955-6. PubMed ID: 9091657
    [No Abstract]   [Full Text] [Related]  

  • 24. Prostate cancer screening.
    Roetzheim RG; Herold AH
    Prim Care; 1992 Sep; 19(3):637-49. PubMed ID: 1384077
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Why PSA testing does have value.
    Kirby M
    Practitioner; 1997 Jul; 241(1576):363. PubMed ID: 9425708
    [No Abstract]   [Full Text] [Related]  

  • 26. Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer.
    Carter HB; Epstein JI; Chan DW; Fozard JL; Pearson JD
    JAMA; 1997 May; 277(18):1456-60. PubMed ID: 9145718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early-stage prostate cancer, PSA screening rates decline.
    Printz C
    Cancer; 2016 Mar; 122(6):825. PubMed ID: 26938268
    [No Abstract]   [Full Text] [Related]  

  • 28. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening.
    Catalona WJ; Smith DS; Wolfert RL; Wang TJ; Rittenhouse HG; Ratliff TL; Nadler RB
    JAMA; 1995 Oct; 274(15):1214-20. PubMed ID: 7563511
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate Cancer Screening and the Associated Controversy.
    Tabayoyong W; Abouassaly R
    Surg Clin North Am; 2015 Oct; 95(5):1023-39. PubMed ID: 26315521
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection.
    Ross KS; Carter HB; Pearson JD; Guess HA
    JAMA; 2000 Sep; 284(11):1399-405. PubMed ID: 10989402
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PSA and the detection of prostate cancer.
    Robbins AS
    JAMA; 1994 Jan; 271(3):192-3. PubMed ID: 7506314
    [No Abstract]   [Full Text] [Related]  

  • 32. Screening for prostate cancer: the role of prostate-specific antigen.
    Ferrer RL
    Md Med J; 1996 Nov; 45(11):938-40. PubMed ID: 8942171
    [No Abstract]   [Full Text] [Related]  

  • 33. Free serum prostate-specific antigen and screening for prostate cancer.
    Bangma CH; Kranse R; Schröder FH
    JAMA; 1996 Mar; 275(11):837-8. PubMed ID: 8596217
    [No Abstract]   [Full Text] [Related]  

  • 34. Prostate specific antigen testing for prostate cancer.
    Thornton H; Dixon-Woods M
    BMJ; 2002 Oct; 325(7367):725-6. PubMed ID: 12364286
    [No Abstract]   [Full Text] [Related]  

  • 35. Prostate-specific antigen and the early diagnosis of prostate cancer.
    Caplan A; Kratz A
    Am J Clin Pathol; 2002 Jun; 117 Suppl():S104-8. PubMed ID: 14569806
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostate-cancer screening--what the U.S. Preventive Services Task Force left out.
    Brett AS; Ablin RJ
    N Engl J Med; 2011 Nov; 365(21):1949-51. PubMed ID: 22029759
    [No Abstract]   [Full Text] [Related]  

  • 37. Prostate cancer: enthusiasm for screening.
    Kaye KW
    Med J Aust; 1995 May; 162(10):540-1. PubMed ID: 7539884
    [No Abstract]   [Full Text] [Related]  

  • 38. Possibility of re-screening intervals of more than one year in men with PSA levels of 4.0 ng/ml or less.
    Ito K; Yamamoto T; Ohi M; Takechi H; Kurokawa K; Suzuki K; Yamanaka H
    Prostate; 2003 Sep; 57(1):8-13. PubMed ID: 12886518
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng./ml. Prostate specific antigen.
    Lodding P; Aus G; Bergdahl S; Frösing R; Lilja H; Pihl CG; Hugosson J
    J Urol; 1998 Mar; 159(3):899-903. PubMed ID: 9474178
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [PSA level--is 4.0 ng/ml as upper limit too high].
    Aktuelle Urol; 2005 Jun; 36(3):181-8. PubMed ID: 16001334
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.